Sun Pharma is marrying Organon
Sun Pharma has announced the acquisition of US-based pharmaceutical company Organon for $11.75 billion, marking the largest overseas pharmaceutical deal in India's history. Organon, spun off from Merck & Co. in 2021, reported $6 billion in revenue in 2025 but faces challenges including slowing sales, a high debt load, and past controversies over sales practices. Despite these issues, the deal is expected to enhance Sun Pharma's global footprint and product portfolio in women's health and specialty generics.
- ▪Sun Pharma is acquiring Organon for $11.75 billion, the largest overseas pharma deal by an Indian company.
- ▪Organon generated $6 billion in revenue in 2025 but carries a net leverage of nearly 4.5 times due to $8.6 billion in debt.
- ▪The company faced scrutiny in 2025 for inflating Nexplanon sales, leading to a 3–4% decline in annual revenue.
- ▪Sun Pharma has historically used acquisitions to grow, including past deals for Taro Pharmaceuticals and Ranbaxy Laboratories.
- ▪Organon derives about a third of its revenue from the US, similar to Sun Pharma’s current exposure.
Opening excerpt (first ~120 words) tap to expand
1 May 2026 • Markets Sun Pharma is marrying Organon In today’s Finshots, we briefly explain Sun Pharma’s acquisition of Organon.But here’s a quick sidenote before we begin. If you’re someone who loves keeping tabs on the world of business and finance, hit subscribe if you haven’t already. And if you’re already a subscriber, thank you! Maybe forward this to someone who’d enjoy our stories but hasn’t discovered us yet.Now, on to today’s story.The StoryA few days ago, the largest overseas pharmaceutical deal in India’s history was announced. Sun Pharmaceutical Industries said it would acquire US-based Organon & Co. for $11.75 billion.So let’s skip the fluff and get straight to the meat of this deal.Sun Pharma needs little introduction.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Hacker News: Newest.